For the quarter ended March 31, 2025, Calamos Growth Fund returned -10.55% (Class I shares at NAV) versus the S&P 1500 Growth ...

SLB's digital, carbon capture, and lithium ventures drive growth amidst cyclical challenges. Read more on how SLB is ...

Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. While Novo lost share to Eli Lilly's once-weekly Trulicity, Ozempic and Rybelsus ...

Moderated discussion with founding physician of the Brain Tumor Center and Director of Neuro-Oncology at Piedmont Atlanta Hospital, Dr. Erin Dunbar HOUSTON, TX / ACCESS Newswire / June 24, 2025 / CNS ...